Short-term safety and efficacy of a single intravitreal bevacizumab injection for the management of polypoidal choroidal vasculopathy

Ji Hun Song, Suk Ho Byeon, Sungchul Lee, Hyoung Jun Koh, Oh Woong Kwon

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Aims: To evaluate the short-term safety and efficacy of a single intravitreal bevacizumab injection in patients with polypoidal choroidal vasculopathy (PCV). Methods: The records of patients treated with intravitreal bevacizumab for PCV were retrospectively reviewed. All patients were evaluated by complete ophthalmic examination, optical coherence tomography and fluorescein and indocyanine green angiography. Changes in visual acuity and central retinal thickness (CRT) over 3 months were the main outcome measures. Results: Nineteen eyes of 18 patients were included. No serious ocular or systemic adverse events were observed. The median baseline visual acuity and CRT were 20/100 and 230 μm, respectively. After 1 month, there was no significant improvement in median visual acuity (20/80+1; p = 0.055), but median CRT had decreased significantly (160 μm; p < 0.001). After 3 months (data available for 17 eyes), both median visual acuity (20/63-2; p = 0.001) and CRT (190 μm; p = 0.007) showed significant improvements over baseline values. Conclusions: Intravitreal bevacizumab therapy for PCV was well tolerated over the 3-month follow-up period. Short-term results are promising, but further studies are necessary to evaluate long-term efficacy.

Original languageEnglish
Pages (from-to)85-92
Number of pages8
JournalOphthalmologica
Volume223
Issue number2
DOIs
Publication statusPublished - 2009 Feb 1

Fingerprint

Intravitreal Injections
Visual Acuity
Safety
Indocyanine Green
Optical Coherence Tomography
Fluorescein
Angiography
Outcome Assessment (Health Care)
Bevacizumab
Therapeutics

All Science Journal Classification (ASJC) codes

  • Ophthalmology
  • Sensory Systems

Cite this

@article{66753c7f2a15438fb885f920249d63a0,
title = "Short-term safety and efficacy of a single intravitreal bevacizumab injection for the management of polypoidal choroidal vasculopathy",
abstract = "Aims: To evaluate the short-term safety and efficacy of a single intravitreal bevacizumab injection in patients with polypoidal choroidal vasculopathy (PCV). Methods: The records of patients treated with intravitreal bevacizumab for PCV were retrospectively reviewed. All patients were evaluated by complete ophthalmic examination, optical coherence tomography and fluorescein and indocyanine green angiography. Changes in visual acuity and central retinal thickness (CRT) over 3 months were the main outcome measures. Results: Nineteen eyes of 18 patients were included. No serious ocular or systemic adverse events were observed. The median baseline visual acuity and CRT were 20/100 and 230 μm, respectively. After 1 month, there was no significant improvement in median visual acuity (20/80+1; p = 0.055), but median CRT had decreased significantly (160 μm; p < 0.001). After 3 months (data available for 17 eyes), both median visual acuity (20/63-2; p = 0.001) and CRT (190 μm; p = 0.007) showed significant improvements over baseline values. Conclusions: Intravitreal bevacizumab therapy for PCV was well tolerated over the 3-month follow-up period. Short-term results are promising, but further studies are necessary to evaluate long-term efficacy.",
author = "Song, {Ji Hun} and Byeon, {Suk Ho} and Sungchul Lee and Koh, {Hyoung Jun} and Kwon, {Oh Woong}",
year = "2009",
month = "2",
day = "1",
doi = "10.1159/000175312",
language = "English",
volume = "223",
pages = "85--92",
journal = "Ophthalmologica",
issn = "0030-3755",
publisher = "S. Karger AG",
number = "2",

}

Short-term safety and efficacy of a single intravitreal bevacizumab injection for the management of polypoidal choroidal vasculopathy. / Song, Ji Hun; Byeon, Suk Ho; Lee, Sungchul; Koh, Hyoung Jun; Kwon, Oh Woong.

In: Ophthalmologica, Vol. 223, No. 2, 01.02.2009, p. 85-92.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Short-term safety and efficacy of a single intravitreal bevacizumab injection for the management of polypoidal choroidal vasculopathy

AU - Song, Ji Hun

AU - Byeon, Suk Ho

AU - Lee, Sungchul

AU - Koh, Hyoung Jun

AU - Kwon, Oh Woong

PY - 2009/2/1

Y1 - 2009/2/1

N2 - Aims: To evaluate the short-term safety and efficacy of a single intravitreal bevacizumab injection in patients with polypoidal choroidal vasculopathy (PCV). Methods: The records of patients treated with intravitreal bevacizumab for PCV were retrospectively reviewed. All patients were evaluated by complete ophthalmic examination, optical coherence tomography and fluorescein and indocyanine green angiography. Changes in visual acuity and central retinal thickness (CRT) over 3 months were the main outcome measures. Results: Nineteen eyes of 18 patients were included. No serious ocular or systemic adverse events were observed. The median baseline visual acuity and CRT were 20/100 and 230 μm, respectively. After 1 month, there was no significant improvement in median visual acuity (20/80+1; p = 0.055), but median CRT had decreased significantly (160 μm; p < 0.001). After 3 months (data available for 17 eyes), both median visual acuity (20/63-2; p = 0.001) and CRT (190 μm; p = 0.007) showed significant improvements over baseline values. Conclusions: Intravitreal bevacizumab therapy for PCV was well tolerated over the 3-month follow-up period. Short-term results are promising, but further studies are necessary to evaluate long-term efficacy.

AB - Aims: To evaluate the short-term safety and efficacy of a single intravitreal bevacizumab injection in patients with polypoidal choroidal vasculopathy (PCV). Methods: The records of patients treated with intravitreal bevacizumab for PCV were retrospectively reviewed. All patients were evaluated by complete ophthalmic examination, optical coherence tomography and fluorescein and indocyanine green angiography. Changes in visual acuity and central retinal thickness (CRT) over 3 months were the main outcome measures. Results: Nineteen eyes of 18 patients were included. No serious ocular or systemic adverse events were observed. The median baseline visual acuity and CRT were 20/100 and 230 μm, respectively. After 1 month, there was no significant improvement in median visual acuity (20/80+1; p = 0.055), but median CRT had decreased significantly (160 μm; p < 0.001). After 3 months (data available for 17 eyes), both median visual acuity (20/63-2; p = 0.001) and CRT (190 μm; p = 0.007) showed significant improvements over baseline values. Conclusions: Intravitreal bevacizumab therapy for PCV was well tolerated over the 3-month follow-up period. Short-term results are promising, but further studies are necessary to evaluate long-term efficacy.

UR - http://www.scopus.com/inward/record.url?scp=56349123897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56349123897&partnerID=8YFLogxK

U2 - 10.1159/000175312

DO - 10.1159/000175312

M3 - Article

VL - 223

SP - 85

EP - 92

JO - Ophthalmologica

JF - Ophthalmologica

SN - 0030-3755

IS - 2

ER -